Revenue grew 44% at constant currency in H1 2026, driven by US clinical adoption and rapid international expansion of CellTolerance, with profitability targeted by end-2027. Financial visibility is secured beyond 2027 following capital raises and debt reduction.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.